Ticker,Title,Link
AIM,AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research,8/20/2024 2:30:00 PM
AIM,Hemispherx Biopharma earnings preview: what Wall Street is expecting,8/16/2024 3:01:13 PM
AIM,AIM ImmunoTech Q2 2024 Earnings Preview,8/15/2024 7:52:37 PM
AIM,"AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast",8/13/2024 3:05:00 PM
AIM,AIM ImmunoTech Announces Release of the Next CEO Corner Segment,7/29/2024 3:15:00 PM
AIM,AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy,7/24/2024 2:50:00 PM
AIM,AIM ImmunoTech Announces Release of the Next CEO Corner Segment,7/3/2024 2:55:00 PM
AIM,AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference,6/10/2024 2:55:00 PM
AIM,AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series,6/3/2024 3:15:00 PM
AIM,AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering,5/31/2024 2:30:00 PM
AIM,AIM ImmunoTech to Participate in Two Upcoming Investor Conferences,5/20/2024 3:15:00 PM
AIM,Buy Rating Affirmed: AIM ImmunoTech’s Ampligen Shows Promising Oncology Pipeline Progress,5/17/2024 5:55:34 PM
AIM,AIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024,5/16/2024 3:52:41 PM
AIM,Notable earnings before Thursday's open,5/15/2024 3:47:59 PM
AIM,"AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast",5/9/2024 2:50:00 PM
AIM,AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®,5/6/2024 2:30:00 PM
AIM,Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO),4/30/2024 10:40:21 AM
AIM,AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer,4/29/2024 2:55:00 PM
AIM,AIM ImmunoTech Announces Release of the Next CEO Corner Segment,4/25/2024 2:45:00 PM
AIM,AIM ImmunoTech files to sell 9.98M shares of common stock for holders,4/19/2024 9:12:59 PM
AIM,AIM ImmunoTech Announces Release of the Next CEO Corner Segment,4/18/2024 2:45:00 PM
AIM,"AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs",4/15/2024 2:55:00 PM
AIM,AIM ImmunoTech Announces Release of the Next CEO Corner Segment,4/11/2024 5:00:00 PM
AIM,Aim ImmunoTech Announces Positive Data From Ampligen Study In Combination With Pembrolizumab ,4/10/2024 3:17:52 PM
AIM,Ampligen’s Prospects in Post-COVID Fatigue and Cancer Treatment: A Strong Buy Recommendation,4/3/2024 7:05:26 PM
AIM,"AIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023",4/2/2024 3:52:52 PM
AIM,AIM ImmunoTech FY 2023 Earnings Preview,4/1/2024 5:48:59 PM
AIM,AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference,3/28/2024 1:05:00 PM
AIM,"AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast",3/26/2024 2:05:00 PM
AIM,AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research,3/25/2024 2:05:00 PM
AIM,AIM ImmunoTech Announces Release of the Next CEO Corner Segment,3/22/2024 1:55:00 PM
AIM,AIM ImmunoTech Announces Release of the Next CEO Corner Segment,3/20/2024 2:25:00 PM
AIM,AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity,3/15/2024 1:45:00 PM
AIM,AIM ImmunoTech Announces Launch of CEO Corner Platform,3/7/2024 2:45:00 PM
AIM,AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update,2/29/2024 2:45:00 PM
AIM,Buy Rating Affirmed for AIM ImmunoTech Amidst Promising Trials and Product Pipeline Developments,2/15/2024 6:45:16 PM
AIM,AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of...,2/14/2024 2:55:00 PM
AIM,AIM ImmunoTech Touts Ampligen’s Post-COVID Study Success,2/10/2024 9:20:06 AM
AIM,AIM stock dips amid mixed results for post-COVID fatigue therapy,2/8/2024 4:37:46 PM
AIM,AIM ImmunoTech Gets Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of Ampligen ,1/24/2024 4:40:43 PM
AIM,AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer,1/22/2024 2:55:00 PM
AIM,AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer,1/10/2024 2:45:00 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday,1/9/2024 12:30:19 PM
AIM,"Delaware Court Rules In Favor Of AIM ImmunoTech, Upholds Activist Group's Board Nominations Invalid ",12/29/2023 2:48:08 PM
AIM,AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents,11/27/2023 3:05:00 PM
AIM,AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions,11/21/2023 6:00:00 PM
AIM,Strong Financial Position and Promising Clinical Trials Bolster Buy Rating for AIM ImmunoTech: An Analysis by Jason McCarthy,11/16/2023 5:06:20 PM
AIM,AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update,11/15/2023 1:30:00 PM
AIM,AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic...,11/14/2023 4:00:00 PM
AIM,"AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast",11/9/2023 2:05:00 PM
AIM,AIM ImmunoTech Announces Positive Data From Phase 2 Study Of Ampligen In Recurrent Ovarian Cancer ,11/8/2023 3:09:47 PM
AIM,AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting,10/30/2023 1:55:00 PM
AIM,"AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs",10/17/2023 2:45:00 PM
AIM,Kognitiv Launches AI-Native Kognitiv Ignite: Revolutionary Outcome-Based Customer Engagement Solution,9/27/2023 3:54:00 PM
AIM,AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care,9/22/2023 3:05:00 PM
AIM,"AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with...",9/11/2023 7:00:00 PM
AIM,AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference,9/5/2023 3:05:00 PM
AIM,AI-Media and Middleman Announce Ad Insertion Partnership,8/31/2023 4:00:00 PM
AIM,AI-Media's AI-Powered LEXI Captioning Tool Kit Raises the Bar,8/24/2023 4:00:00 PM
AIM,Why AMC Entertainment Shares Are Trading Lower By 21%; Here Are 20 Stocks Moving Premarket,8/23/2023 2:34:21 PM
AIM,"Analysts Are Bullish on These Healthcare Stocks: AIM ImmunoTech (AIM), Microbot Medical (MBOT)",8/17/2023 4:30:11 PM
AIM,AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update,8/15/2023 12:45:00 PM
AIM,AIM ImmunoTech Q2 2023 Earnings Preview,8/14/2023 6:27:27 PM
AIM,Kognitiv Announces Sale of Hospitality Technology Business to Valsoft Corp.,8/8/2023 6:35:00 PM
AIM,Why PacWest Bancorp Shares Are Trading Higher By Over 35%; Here Are 20 Stocks Moving Premarket,7/26/2023 2:09:19 PM
AIM,Why Senmiao Technology Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket,7/13/2023 2:12:36 PM
AIM,Why Tivic Health Systems Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket,7/10/2023 2:11:41 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday,7/7/2023 11:18:23 AM
AIM,Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket,7/6/2023 2:03:56 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday,6/29/2023 11:27:32 AM
AIM,Why Oncorus Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket,6/12/2023 2:24:01 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday,5/22/2023 11:31:52 AM
AIM,Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and AIM ImmunoTech (AIM),5/18/2023 7:00:39 PM
AIM,Kognitiv welcomes Jon Ott as Chief Revenue Officer,5/8/2023 4:40:00 PM
AIM,Ascendiant Remains a Buy on AIM ImmunoTech (AIM),4/7/2023 8:15:19 AM
AIM,Maxim Group Sticks to Their Buy Rating for AIM ImmunoTech (AIM),4/5/2023 11:25:09 AM
AIM,"AIM ImmunoTech GAAP EPS of -$0.40, revenue of $0.14M",4/3/2023 10:37:57 AM
AIM,Notable earnings after Friday's close,3/30/2023 9:35:02 PM
AIM,KOGNITIV LAUNCHES POWERFUL NEW AI-DRIVEN KOGNITIV PULSE,3/28/2023 7:39:00 PM
AIM,AIM Immunotech reports new analysis of Ampligen as a potential therapy against Ebola virus disease,3/8/2023 3:20:38 PM
AIM,AIM ImmunoTech (AIM) Receives a Buy from Maxim Group,3/1/2023 7:25:06 PM
AIM,Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket,2/28/2023 1:57:23 PM
AIM,Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket,2/24/2023 1:56:27 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday,2/17/2023 12:39:01 PM
AIM,Why Axcella Health Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket,2/16/2023 1:54:30 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday,1/31/2023 12:36:29 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday,1/25/2023 12:29:15 PM
AIM,Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket,1/19/2023 1:48:19 PM
AIM,Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,1/17/2023 7:21:03 PM
AIM,Why Lightning eMotors Shares Are Trading Lower By 9%; Here Are 20 Stocks Moving Premarket,1/11/2023 1:58:17 PM
AIM,Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session,1/4/2023 7:17:01 PM
AIM,Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket,12/23/2022 1:51:57 PM
AIM,Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket,12/19/2022 12:13:37 PM
AIM,Maxim Group Remains a Buy on AIM ImmunoTech (AIM),11/16/2022 5:55:08 PM
AIM,AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update,11/15/2022 1:00:00 PM
AIM,"AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the...",11/14/2022 1:00:00 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday,11/7/2022 12:28:17 PM
AIM,AIM ImmunoTech soars on FDA orphan drug tag for Ampligen to treat Ebola virus disease,11/2/2022 12:51:29 PM
AIM,AIM ImmunoTech says court denies activist request on board nominees,10/31/2022 1:35:37 PM
AIM,AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions,10/12/2022 2:45:00 PM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday,10/11/2022 11:23:00 AM
AIM,Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket,9/28/2022 1:17:23 PM
AIM,AIM ImmunoTech to Present at the Virtual Investor Long COVID Event,9/21/2022 2:45:00 PM
AIM,TRADE X Opens Its B2B Trading Platform to Automotive Buyers in the Dominican Republic,9/7/2022 3:31:00 PM
AIM,AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care,9/6/2022 1:30:00 PM
AIM,AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma,8/30/2022 1:30:00 PM
AIM,Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket,8/25/2022 2:12:25 PM
AIM,AIM ImmunoTech Commences Phase 2 Study Of Ampligen For Pancreatic Cancer Treatment ,8/18/2022 3:28:21 PM
AIM,Why IZEA Worldwide Shares Are Trading Higher By Over 30%: Here Are 37 Stocks Moving Premarket,8/16/2022 12:25:23 PM
AIM,AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update,8/15/2022 2:05:00 PM
AIM,Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket,8/1/2022 12:43:30 PM
AIM,AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID,7/28/2022 3:10:00 PM
AIM,Why Is F45 Training Holdings Down By 56%? Here Are 28 Stocks Moving In Wednesday's Pre-Market Session,7/27/2022 12:34:56 PM
AIM,Why Is United Airlines Down By Over 6%? Here Are 25 Stocks Moving In Thursday's Pre-Market Session,7/21/2022 11:53:52 AM
AIM,AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional...,7/20/2022 2:05:00 PM
AIM,AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid,7/18/2022 2:00:00 PM
AIM,AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series,7/14/2022 2:05:00 PM
AIM,This Healthcare Stock is Surging By Over 21%: Here's 24 Biggest Movers In Tuesday's Pre-Market,7/12/2022 12:14:30 PM
AIM,Aspen Aerogels And 28 Stocks Moving Premarket,6/30/2022 12:33:34 PM
AIM,LiveOne And 24 Stocks Moving Premarket,6/29/2022 12:32:23 PM
AIM,Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session,6/28/2022 1:00:15 PM
AIM,AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing,6/21/2022 2:35:00 PM
AIM,AIM ImmunoTech receives patent coverage in Netherlands for potential COVID-19 treatment,6/13/2022 2:56:22 PM
AIM,20 Stocks Moving in Wednesday's Pre-Market Session,6/8/2022 11:59:33 AM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday,6/3/2022 11:27:27 AM
AIM,AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference,5/19/2022 2:00:00 PM
AIM,AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program,5/18/2022 2:00:00 PM
AIM,AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update,5/16/2022 1:05:00 PM
AIM,"AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022",5/12/2022 2:05:00 PM
AIM,"The Daily Biotech Pulse: Limited Use Of JNJ's COVID-19 Shot, Myovant-Pfizer's Relugolix Application Delayed, Gain Therapeutics' Parkinson's Data",5/6/2022 2:54:29 PM
AIM,20 Stocks Moving in Tuesday's Pre-Market Session,5/3/2022 12:51:19 PM
AIM,18 Stocks Moving in Tuesday's Pre-Market Session,4/26/2022 12:00:06 PM
AIM,26 Stocks Moving in Monday's Pre-Market Session,4/25/2022 12:13:01 PM
AIM,AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies,4/21/2022 2:05:00 PM
AIM,54 Biggest Movers From Yesterday,4/20/2022 11:43:34 AM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday,4/19/2022 11:24:54 AM
AIM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday,4/14/2022 11:37:07 AM
AIM,"AIM, PTE and PHIO among mid-day movers",4/12/2022 4:48:09 PM
AIM,AIM ImmunoTech Up 8% As Its Ampligen To Treat Breast Cancer Meets Primary Goal ,4/11/2022 4:10:18 PM
AIM,"Seeking Alpha's Catalyst Watch: Healthcare spotlight on AACR, Bed Bath & Beyond earnings and Elon Musk's TED talk",4/8/2022 7:00:00 PM
AIM,AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update,3/31/2022 10:05:00 PM
AIM,AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress,3/28/2022 1:35:00 PM
AIM,"Long COVID, the next frontier for vaccine and drug developers",3/25/2022 5:36:37 PM
AIM,"AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod,...",3/24/2022 3:10:00 PM
AIM,AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest,3/23/2022 1:05:00 PM
AIM,AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer,3/16/2022 12:05:00 PM
AIM,AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting ,3/9/2022 1:35:00 PM
AIM,AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic...,3/8/2022 7:59:32 PM
AIM,"AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline",3/7/2022 2:05:00 PM
AIM,"AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer",3/3/2022 2:35:00 PM
AIM,AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar,1/26/2022 2:05:00 PM
AIM,AIM ImmunoTech reports positive data from phase1/2 trial in ovarian cancer,1/24/2022 8:53:22 PM
AIM,AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference,1/19/2022 2:35:00 PM
AIM,AIM ImmunoTech’s Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza,12/9/2021 1:20:00 PM
AIM,AIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences,12/6/2021 1:25:00 PM
AIM,AIM ImmunoTech Provides Third Quarter 2021 Business Update,11/16/2021 1:00:00 PM
AIM,AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer,10/19/2021 1:25:00 PM
AIM,AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy,10/6/2021 1:25:00 PM
AIM,AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer,10/4/2021 3:20:00 PM
AIM,"The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug",9/30/2021 1:43:13 PM
AIM,AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19,9/28/2021 3:20:00 PM
AIM,AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses,9/27/2021 3:20:00 PM
AIM,AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction,9/21/2021 1:25:00 PM
AIM,AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen,9/20/2021 3:15:00 PM
AIM,AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction,9/8/2021 3:00:00 PM
AIM,AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD),8/25/2021 3:00:00 PM
AIM,AIM ImmunoTech Provides Second Quarter 2021 Business Update,8/17/2021 3:00:00 PM
AIM,AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.,8/16/2021 1:25:00 PM
AIM,Aimia Declares Preferred Share Dividends,8/13/2021 1:00:00 PM
AIM,B2B Automotive Trading Platform TRADE X Secures C$44 Million in New Equity Financing for Global Expansion,7/27/2021 2:32:00 PM
AIM,AIM Immuno : Phase 2a Trial To Test Ampligen As Intranasal Antiviral Prophylactic Therapy ,7/9/2021 2:25:59 PM
AIM,"AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET",7/6/2021 8:15:00 PM
AIM,Aimia completes sale of investment in BIGLIFE to AirAsia,6/28/2021 2:30:00 PM
AIM,AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen,6/21/2021 3:00:00 PM
AIM,Aimia Announces Normal Course Issuer Bid to Repurchase up to 7.3 Million Shares,6/17/2021 2:00:00 PM
AIM,AIM ImmunoTech’s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2,6/14/2021 1:15:00 PM
AIM,AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen,5/27/2021 2:45:00 PM
AIM,AIM ImmunoTech Announces Positive Safety Data from the Third Cohort of Its Phase 1 Intranasal Clinical Trial,5/26/2021 3:15:00 PM
AIM,AIM ImmunoTech Provides First Quarter 2021 Business Update,5/18/2021 1:30:00 PM
AIM,AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo ,5/3/2021 1:30:00 PM
AIM,AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and...,4/27/2021 1:15:00 PM
AIM,AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and...,4/7/2021 3:15:00 PM
AIM,AIM ImmunoTech Reports 2020 Year-End Financial Results,3/31/2021 3:15:00 PM
AIM,AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with COVID-19,3/22/2021 1:45:00 PM
AIM,AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th,3/11/2021 1:00:00 PM
AIM,8 Biotech Penny Stocks for Investors to Watch,3/10/2021 4:54:25 PM
AIM,AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study,3/8/2021 3:15:00 PM
AIM,7 Robinhood Stocks To Buy for Your Penny Stocks Portfolio,3/5/2021 11:11:35 AM
AIM,AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th,3/4/2021 12:50:00 PM
AIM,AIM ImmunoTech’s Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer,2/24/2021 3:15:00 PM
AIM,7 Biotech Stocks Focused on Chronic Covid Treatment,2/22/2021 6:30:49 PM
AIM,AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy,2/16/2021 3:15:00 PM
AIM,AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands,2/10/2021 3:15:00 PM
AIM,101 Biggest Movers From Friday,2/8/2021 11:16:27 AM
AIM,AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials,2/5/2021 12:50:00 PM
AIM,60 Stocks Moving In Thursday's Mid-Day Session,2/4/2021 6:00:19 PM
AIM,AIM ImmunoTech in pact with a university for proposed Ampligen studyin COVID-19,1/29/2021 2:26:59 PM
AIM,"AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET",1/15/2021 12:45:00 PM
AIM,AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date,1/11/2021 12:45:00 PM
AIM,"Dosing underway in AIM Immunotech's ""long hauler"" part of ampligen COVID-19 trial",1/6/2021 5:21:41 PM
AIM,AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’,12/24/2020 3:05:04 PM
AIM,"Fitbit, Soligenix leads premarket losers' pack",12/22/2020 1:25:25 PM
AIM,55 Stocks Moving In Monday's Mid-Day Session,12/21/2020 6:04:18 PM
AIM,Healthcare tops premarket gainers list,12/18/2020 1:21:34 PM
AIM,AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19,11/25/2020 12:45:00 PM
AIM,"AHT, FCEL, AIM and MARA among midday movers",11/23/2020 5:42:55 PM
AIM,AIM ImmunoTech Provides Third Quarter 2020 Business Update,11/13/2020 1:30:00 PM
AIM,AIM ImmunoTech Announces PLOS ONE’s Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen’s Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS),11/2/2020 3:00:00 PM
AIM,BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year,10/30/2020 3:00:10 PM
AIM,AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th,10/22/2020 1:30:10 PM
AIM,AIM ImmunoTech to recruit long-term COVID-19 patients with chronic fatigue in Ampligen trial,10/6/2020 4:35:50 PM
AIM,Aim ImmunoTech News: Why AIM Stock Is Shooting 22% Higher Today,9/22/2020 6:41:04 PM
AIM,AIM ImmunoTech Highlights Start of Recruitment in Roswell Park Clinical Trial Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19,9/16/2020 6:50:00 AM
AIM,AIM ImmunoTech to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14th,9/10/2020 6:50:00 AM
AIM,"AIM ImmunoTech CEO to Participate in Virtual Panel: 'New Approaches to COVID-19: Hidden Breakthroughs,' on Thursday, September 10th",9/8/2020 6:50:00 AM
AIM,AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19,8/27/2020 9:15:00 AM
AIM,AIM ImmunoTech to Present at The LD 500 Virtual Conference on September 1st,8/25/2020 6:55:00 AM
AIM,AIM ImmunoTech Provides Second Quarter 2020 Business Update and Reports Progress in Both COVID-19 and Cancer Trials,8/17/2020 6:55:00 AM
AIM,"49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020",8/3/2020 8:00:00 AM
AIM,"AIM ImmunoTech to Present at the SNN Network Virtual Investor Conference on Monday, August 3rd",7/27/2020 6:55:00 AM
AIM,AIM ImmunoTech Seduces With Coronavirus Treatment Potential,7/17/2020 1:02:51 PM
AIM,AIM ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients...,7/9/2020 6:30:00 AM
AIM,"AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as...",7/6/2020 9:00:00 AM
AIM,AIM ImmunoTech Added to Russell Microcap(R) Index,6/29/2020 6:55:00 AM
AIM,"2 Pros, 2 Cons for Buying AIM ImmunoTech",6/17/2020 3:35:24 PM
AIM,Coronavirus Research Is the Key for AIM ImmunoTech Stock,6/15/2020 1:10:53 PM
AIM,AIM ImmunoTech files provisional patent for the use of Ampligen in COVID-19,6/11/2020 1:27:38 PM
AIM,"VMW, MRVL among premarket gainers",5/29/2020 1:21:39 PM
AIM,Sorrento Therapeutics leads healthcare gainers; electroCore and Co-Diagnostics among losers,5/15/2020 3:06:31 PM
AIM,"ACB, AIM, CVET and NEWR among after-hours movers",5/14/2020 9:42:32 PM
AIM,AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference,4/29/2020 6:30:00 AM
AIM,"BBBY, DVAX among premarket gainers",4/28/2020 1:22:08 PM
AIM,AIM ImmunoTech’s CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020,4/20/2020 6:30:00 AM
AIM,AIM Stock Is a Moonshot That Lacks the Fuel,4/9/2020 12:26:07 PM
AIM,Ignore the Coronavirus Catalyst for ABBV Stock,4/8/2020 2:03:52 PM
AIM,"CIM, EURN among premarke losers",4/7/2020 1:10:33 PM
AIM,"AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use...",4/6/2020 6:30:00 PM
AIM,Don’t Pull the Trigger on AIM ImmunoTech Stock,4/2/2020 7:06:50 PM
AIM,"NVTA, AOBC, OMI and PVH among after-hours movers",4/1/2020 9:35:20 PM
AIM,AIM ImmunoTech Reports 2019 Year-end Financial Results,3/31/2020 6:45:00 AM
AIM,"OMI, PSTV, GRPN and WMC among midday movers",3/30/2020 4:40:14 PM
AIM,Read the Label Before Buying AIM Stock,3/27/2020 3:28:44 PM
AIM,AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic,3/26/2020 8:00:00 AM
AIM,"SOHO, TLRY, CPLG and BLCM among midday movers",3/13/2020 4:44:42 PM
AIM,Stocks Double And Tripled In Value From Coronavirus ,3/12/2020 1:27:04 PM
AIM,GT Biopharma News: GTBP Stock Spikes 26% on Coronavirus Treatment Hopes,3/10/2020 7:38:15 PM
AIM,AIM ImmunoTech News: AIM Stock Skyrockets 208% on Hopes for COVID-19 Treatment,3/9/2020 6:50:59 PM
AIM,"MRVL, VIPS among premarket gainers",3/5/2020 2:11:11 PM
AIM,"OCUL, AIM, INFN and OMI among midday movers",3/4/2020 5:39:09 PM
AIM,Healthcare dominates premarket losers amidst coronavirus situation,3/3/2020 2:23:03 PM
AIM,"NVAX, AIM, KPTI and CEI among midday movers",3/2/2020 5:40:16 PM
AIM,"DYNT, ALT, GKOS and VIR among midday movers",2/28/2020 5:40:28 PM
AIM,"WLL, SPEX, CODX and AIM among midday movers",2/27/2020 6:00:55 PM
AIM,"TSLA, KR among premarket gainers",2/18/2020 2:15:56 PM
AIM,"INO, CRSP among premarket gainers",2/13/2020 2:14:49 PM
AIM,"AIM, IO, WLL and BBBY among midday losers",2/12/2020 5:43:55 PM
AIM,AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus ,2/11/2020 6:30:00 AM
AIM,AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies,2/5/2020 6:30:00 AM
AIM,AIM ImmunoTech to Present at the Investor Summit in Philadelphia,12/11/2019 12:20:00 PM
AIM,AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020,12/4/2019 6:30:00 AM
AIM,CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019,11/15/2019 10:25:00 AM
AIM,AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference ,10/23/2019 6:30:00 AM
AIM,AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified,10/7/2019 6:30:00 AM
AIM,"AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering",9/25/2019 9:50:00 AM
AIM,"AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the...",9/24/2019 6:30:00 AM
AIM,"6 Top Gainers In Healthcare Sector (AIM, EDSA, ARAV…) ",9/20/2019 3:39:05 AM
AIM,AIM ImmunoTech Inc. Announces the U.S. Department of Defense’s Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast...,9/19/2019 6:50:00 AM
